Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.

Bremm M, Pfeffermann LM, Cappel C, Katzki V, Erben S, Betz S, Quaiser A, Merker M, Bonig H, Schmidt M, Klingebiel T, Bader P, Huenecke S, Rettinger E.

Front Immunol. 2019 May 31;10:1218. doi: 10.3389/fimmu.2019.01218. eCollection 2019.

2.

New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?

Kranzer K, Kalsdorf B, Heyckendorf J, Andres S, Merker M, Hofmann-Thiel S, Bloemberg GV, Hoffmann H, Niemann S, Lange C, Maurer FP.

Am J Respir Crit Care Med. 2019 Apr 26. doi: 10.1164/rccm.201902-0260LE. [Epub ahead of print] No abstract available.

PMID:
31026398
3.

Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.

Polsfuss S, Hofmann-Thiel S, Merker M, Krieger D, Niemann S, Rüssmann H, Schönfeld N, Hoffmann H, Kranzer K.

Clin Infect Dis. 2019 Feb 2. pii: ciz074. doi: 10.1093/cid/ciz074. [Epub ahead of print]

PMID:
30933266
4.

Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.

Merker M, Salzmann-Manrique E, Katzki V, Huenecke S, Bremm M, Bakhtiar S, Willasch A, Jarisch A, Soerensen J, Schulz A, Meisel R, Bug G, Bonig H, Klingebiel T, Bader P, Rettinger E.

Biol Blood Marrow Transplant. 2019 Mar 13. pii: S1083-8791(19)30156-9. doi: 10.1016/j.bbmt.2019.03.004. [Epub ahead of print]

PMID:
30878607
5.

Longitudinal Outbreak of Multidrug-Resistant Tuberculosis in a Hospital Setting, Serbia.

Arandjelović I, Merker M, Richter E, Kohl TA, Savić B, Soldatović I, Wirth T, Vuković D, Niemann S.

Emerg Infect Dis. 2019 Mar;25(3):555-558. doi: 10.3201/eid2503.181220.

6.

Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.

Havlicek J, Dachsel B, Slickers P, Andres S, Beckert P, Feuerriegel S, Niemann S, Merker M, Labugger I.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):147-154. doi: 10.1016/j.diagmicrobio.2018.12.011. Epub 2018 Dec 30.

7.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

PMID:
30559188
8.

Drug-resistance profiling and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia revealed by whole genome sequencing.

Al-Ghafli H, Kohl TA, Merker M, Varghese B, Halees A, Niemann S, Al-Hajoj S.

Infect Drug Resist. 2018 Nov 12;11:2219-2229. doi: 10.2147/IDR.S181124. eCollection 2018.

9.

A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting.

Andres S, Gröschel MI, Hillemann D, Merker M, Niemann S, Kranzer K.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01798-18. doi: 10.1128/AAC.01798-18. Print 2019 Feb.

10.

Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing.

Vaziri F, Kohl TA, Ghajavand H, Kargarpour Kamakoli M, Merker M, Hadifar S, Khanipour S, Fateh A, Masoumi M, Siadat SD, Niemann S.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01477-18. doi: 10.1128/JCM.01477-18. Print 2019 Jan.

PMID:
30404943
11.

Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia.

Merker M, Barbier M, Cox H, Rasigade JP, Feuerriegel S, Kohl TA, Diel R, Borrell S, Gagneux S, Nikolayevskyy V, Andres S, Nübel U, Supply P, Wirth T, Niemann S.

Elife. 2018 Oct 30;7. pii: e38200. doi: 10.7554/eLife.38200.

12.

The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology.

Meehan CJ, Moris P, Kohl TA, Pečerska J, Akter S, Merker M, Utpatel C, Beckert P, Gehre F, Lempens P, Stadler T, Kaswa MK, Kühnert D, Niemann S, de Jong BC.

EBioMedicine. 2018 Nov;37:410-416. doi: 10.1016/j.ebiom.2018.10.013. Epub 2018 Oct 16.

13.

Pathogen-based precision medicine for drug-resistant tuberculosis.

Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M.

PLoS Pathog. 2018 Oct 18;14(10):e1007297. doi: 10.1371/journal.ppat.1007297. eCollection 2018 Oct. No abstract available.

14.

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.

CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz AL, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo YY, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B.

N Engl J Med. 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26.

15.

AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

Bakhtiar S, Salzmann-Manrique E, Hutter M, Krenn T, Duerken M, Faber J, Reinhard H, Kreyenberg H, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Barnbrock A, Schöning S, Willasch AM, Rettinger E, Soerensen J, Klingebiel TE, Jarisch A, Bader P.

Bone Marrow Transplant. 2019 May;54(5):737-745. doi: 10.1038/s41409-018-0341-z. Epub 2018 Sep 26.

PMID:
30258130
16.

Molecular epidemiology and drug resistance patterns of Mycobacterium tuberculosis complex isolates from university students and the local community in Eastern Ethiopia.

Mekonnen A, Merker M, Collins JM, Addise D, Aseffa A, Petros B, Ameni G, Niemann S.

PLoS One. 2018 Sep 17;13(9):e0198054. doi: 10.1371/journal.pone.0198054. eCollection 2018.

17.

Procalcitonin-guided decision-making results in a significant reduction of antibiotic therapy and hospital stay in neonates with suspected early-onset sepsis.

Merker M, Bolliger R, Schuetz P.

BMJ Evid Based Med. 2018 Aug;23(4):154-155. doi: 10.1136/bmjebm-2017-110838. Epub 2018 Mar 9. Review. No abstract available.

PMID:
30054447
18.

Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".

Köser CU, Heyckendorf J, Andres S, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00616-18. doi: 10.1128/AAC.00616-18. Print 2018 Aug. No abstract available.

19.

Is Procalcitonin-Guided Antibiotic Therapy Working in Emergency Department Outpatients?

Bolliger R, Merker M, Wirz Y, Mueller B, Schuetz P.

Ann Emerg Med. 2018 Aug;72(2):226-228. doi: 10.1016/j.annemergmed.2018.03.028. No abstract available.

PMID:
30031515
20.

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials.

Schuetz P, Bolliger R, Merker M, Christ-Crain M, Stolz D, Tamm M, Luyt CE, Wolff M, Schroeder S, Nobre V, Reinhart K, Branche A, Damas P, Nijsten M, Deliberato RO, Verduri A, Beghé B, Cao B, Shehabi Y, Jensen JS, Beishuizen A, de Jong E, Briel M, Welte T, Mueller B.

Expert Rev Anti Infect Ther. 2018 Jul;16(7):555-564. doi: 10.1080/14787210.2018.1496331. Epub 2018 Jul 13. Review.

PMID:
29969320
21.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
22.

Use of antibiotics in the ambulance for sepsis patients: is earlier really better?

Bolliger R, Merker M, Schuetz P.

J Thorac Dis. 2018 Mar;10(3):1239-1241. doi: 10.21037/jtd.2018.02.49. No abstract available.

23.

Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.

Merker M, Meister MT, Rettinger E, Jarisch A, Soerensen J, Willasch A, Huenecke S, Cappel C, Bremm M, Salzmann-Manrique E, Krenn T, Rossig C, Kremens B, Koscielniak E, Klingebiel T, Bader P.

Bone Marrow Transplant. 2018 Jul;53(7):891-894. doi: 10.1038/s41409-018-0088-6. Epub 2018 Jan 24. No abstract available.

PMID:
29367709
24.

A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.

Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, Kranzer K, Fiebig L, Kröger S, Haas W, Hoffmann H, Indra A, Egli A, Cirillo DM, Robert J, Rogers TR, Groenheit R, Mengshoel AT, Mathys V, Haanperä M, Soolingen DV, Niemann S, Böttger EC, Keller PM; MDR-TB Cluster Consortium.

Lancet Infect Dis. 2018 Apr;18(4):431-440. doi: 10.1016/S1473-3099(18)30004-5. Epub 2018 Jan 8. Erratum in: Lancet Infect Dis. 2018 Jan 10;:.

25.

Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge.

Havlicek J, Dachsel B, Slickers P, Andres S, Beckert P, Feuerriegel S, Niemann S, Merker M, Labugger I.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01249-17. doi: 10.1128/JCM.01249-17. Print 2018 Feb.

26.

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb.

27.

The Evolution of Strain Typing in the Mycobacterium tuberculosis Complex.

Merker M, Kohl TA, Niemann S, Supply P.

Adv Exp Med Biol. 2017;1019:43-78. doi: 10.1007/978-3-319-64371-7_3. Review.

PMID:
29116629
28.

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Merker M, Pfirrmann V, Oelsner S, Fulda S, Klingebiel T, Wels WS, Bader P, Rettinger E.

Oncotarget. 2017 Aug 2;8(39):66137-66153. doi: 10.18632/oncotarget.19821. eCollection 2017 Sep 12.

29.

Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.

Merker M, Eichler S, Herrmann AM, Wiendl H, Kleinschnitz C, Göbel K, Meuth SG.

J Neuroimmunol. 2017 Dec 15;313:125-128. doi: 10.1016/j.jneuroim.2017.08.013. Epub 2017 Sep 21.

PMID:
28992973
30.

Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance.

Nakatani Y, Opel-Reading HK, Merker M, Machado D, Andres S, Kumar SS, Moradigaravand D, Coll F, Perdigão J, Portugal I, Schön T, Nair D, Devi KRU, Kohl TA, Beckert P, Clark TG, Maphalala G, Khumalo D, Diel R, Klaos K, Aung HL, Cook GM, Parkhill J, Peacock SJ, Swaminathan S, Viveiros M, Niemann S, Krause KL, Köser CU.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01575-17. doi: 10.1128/AAC.01575-17. Print 2017 Dec.

31.

An application of competitive reporter monitored amplification (CMA) for rapid detection of single nucleotide polymorphisms (SNPs).

Havlicek J, Rivera-Milla E, Slickers P, Andres S, Feuerriegel S, Niemann S, Merker M, Labugger I.

PLoS One. 2017 Aug 29;12(8):e0183561. doi: 10.1371/journal.pone.0183561. eCollection 2017.

32.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
33.

Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays.

Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, Moradigaravand D, Schön T, Andres S, Schleusener V, Omar SV, Coll F, Huang H, Diel R, Ismail N, Parkhill J, de Jong BC, Peto TE, Crook DW, Niemann S, Robledo J, Smith EG, Peacock SJ, Köser CU.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02169-16. doi: 10.1128/AAC.02169-16. Print 2017 Apr.

34.

Impact of Genetic Diversity on the Biology of Mycobacterium tuberculosis Complex Strains.

Niemann S, Merker M, Kohl T, Supply P.

Microbiol Spectr. 2016 Nov;4(6). doi: 10.1128/microbiolspec.TBTB2-0022-2016. Review.

PMID:
27837742
35.

Reply: Call for Regular Susceptibility Testing of Bedaquiline and Delamanid.

Hoffmann H, Hofmann-Thiel S, Merker M, Kohl TA, Niemann S.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1171-1172. No abstract available.

PMID:
27797620
36.

Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing.

Walker TM, Merker M, Kohl TA, Crook DW, Niemann S, Peto TE.

Clin Microbiol Infect. 2017 Mar;23(3):161-166. doi: 10.1016/j.cmi.2016.10.014. Epub 2016 Oct 24. Review.

37.

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.

Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, Dürken M, Faber J, Huenecke S, Cappel C, Bremm M, Willasch A, Bakhtiar S, Jarisch A, Soerensen J, Klingebiel T, Bader P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):87-95. doi: 10.1016/j.bbmt.2016.10.006. Epub 2016 Oct 11.

38.

Raman spectroscopic identification of Mycobacterium tuberculosis.

Stöckel S, Meisel S, Lorenz B, Kloß S, Henk S, Dees S, Richter E, Andres S, Merker M, Labugger I, Rösch P, Popp J.

J Biophotonics. 2017 May;10(5):727-734. doi: 10.1002/jbio.201600174. Epub 2016 Oct 7.

PMID:
27714969
39.

Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.

Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, Kreyenberg H, Bager R, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Ullrich E, Bakhtiar S, Rettinger E, Jarisch A, Soerensen J, Klingebiel TE, Bader P.

Bone Marrow Transplant. 2017 Feb;52(2):201-208. doi: 10.1038/bmt.2016.224. Epub 2016 Sep 19.

PMID:
27643863
40.

Tracing Mycobacterium tuberculosis transmission by whole genome sequencing in a high incidence setting: a retrospective population-based study in East Greenland.

Bjorn-Mortensen K, Soborg B, Koch A, Ladefoged K, Merker M, Lillebaek T, Andersen AB, Niemann S, Kohl TA.

Sci Rep. 2016 Sep 12;6:33180. doi: 10.1038/srep33180.

41.

LOC-SERS: A Promising Closed System for the Identification of Mycobacteria.

Mühlig A, Bocklitz T, Labugger I, Dees S, Henk S, Richter E, Andres S, Merker M, Stöckel S, Weber K, Cialla-May D, Popp J.

Anal Chem. 2016 Aug 16;88(16):7998-8004. doi: 10.1021/acs.analchem.6b01152. Epub 2016 Jul 29.

PMID:
27441738
42.

High functional diversity stimulates diversification in experimental microbial communities.

Jousset A, Eisenhauer N, Merker M, Mouquet N, Scheu S.

Sci Adv. 2016 Jun 24;2(6):e1600124. doi: 10.1126/sciadv.1600124. eCollection 2016 Jun.

43.

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG.

Nat Commun. 2016 May 18;7:11626. doi: 10.1038/ncomms11626.

44.

Vitamin D Deficiency Strongly Predicts Adverse Medical Outcome Across Different Medical Inpatient Populations: Results From a Prospective Study.

Graedel L, Merker M, Felder S, Kutz A, Haubitz S, Faessler L, Kaeslin M, Huber A, Mueller B, Schuetz P.

Medicine (Baltimore). 2016 May;95(19):e3533. doi: 10.1097/MD.0000000000003533.

45.

Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system.

Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Utpatel C, Merker M, Trovato A, Hofmann-Thiel S, Hoffmann H, Cirillo DM.

J Antimicrob Chemother. 2016 Jun;71(6):1532-9. doi: 10.1093/jac/dkw044. Epub 2016 Apr 13.

PMID:
27076101
46.

In reply.

Merker M, Crudu V, Noroc E, Romancenco E, Chesov D, Günther G, Niemann S, Lange C.

Int J Tuberc Lung Dis. 2016 Mar;20(3):424. doi: 10.5588/ijtld.15.1024-2. No abstract available.

PMID:
27046728
47.

Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.

Hoffmann H, Kohl TA, Hofmann-Thiel S, Merker M, Beckert P, Jaton K, Nedialkova L, Sahalchyk E, Rothe T, Keller PM, Niemann S.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):337-40. doi: 10.1164/rccm.201502-0372LE. No abstract available.

48.

Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.

Rettinger E, Huenecke S, Bonig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz A, Klingebiel T, Bader P.

Haematologica. 2016 Apr;101(4):e153-6. doi: 10.3324/haematol.2015.138016. Epub 2016 Jan 14. No abstract available.

49.

Nosocomial transmission of multidrug-resistant tuberculosis.

Crudu V, Merker M, Lange C, Noroc E, Romancenco E, Chesov D, Günther G, Niemann S.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1520-3. doi: 10.5588/ijtld.15.0327.

PMID:
26614195
50.

Tuberculous Lymphadenitis in Ethiopia Predominantly Caused by Strains Belonging to the Delhi/CAS Lineage and Newly Identified Ethiopian Clades of the Mycobacterium tuberculosis Complex.

Biadglegne F, Merker M, Sack U, Rodloff AC, Niemann S.

PLoS One. 2015 Sep 16;10(9):e0137865. doi: 10.1371/journal.pone.0137865. eCollection 2015.

Supplemental Content

Loading ...
Support Center